ADVANZ PHARMA Corp. Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ADVANZ PHARMA Corp. Limited
The SHIELD I trial, for preventing surgical site infections, did not meet its primary and key secondary endpoints, but a subgroup analysis did, while COVID-19 may have muddled results.
Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.
Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.
Amylyx is funding research at the Sunnybrook Research Institute to investigate Bax and Bak inhibition in neurodegenerative disease. Repertoire looks into HPV+ cancer with Memorial Sloan Kettering.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- ADVANZ PHARMA
- ADVANZ PHARMA Corp. Limited
- Amdipharm Mercury Limited
- Concordia Healthcare Corp.
- Concordia International Corp.
- Concordia Laboratories, Inc.
- Concordia Pharmaceuticals, Inc.
- Covis Pharma S.à.r.l, Covis Injectables, S.à.r.l
- Correvio Pharma Corp
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.